Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
Open Access
- 14 February 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (4) , 498-511
Abstract
Chimeric antigen receptor (CAR)–modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most of them with CD19-positive disease. Therefore, new therapeutic strategies are clearly needed. Here, we report a comprehensive study comparing engineered T cells either expressing a second-generation anti-CD19 CAR (CAR-T19) or secreting a CD19/CD3-targeting bispecific T-cell engager antibody (STAb-T19). We found that STAb-T19 cells are more effective than CAR-T19 cells at inducing cytotoxicity, avoiding leukemia escape in vitro, and preventing relapse in vivo. We observed that leukemia escape in vitro is associated with rapid and drastic CAR-induced internalization of CD19 that is coupled with lysosome-mediated degradation, leading to the emergence of transiently CD19-negative leukemic cells that evade the immune response of engineered CAR-T19 cells. In contrast, engineered STAb-T19 cells induce the formation of canonical immunologic synapses and prevent the CD19 downmodulation observed in anti-CD19 CAR-mediated interactions. Although both strategies show similar efficacy in short-term mouse models, there is a significant difference in a long-term patient-derived xenograft mouse model, where STAb-T19 cells efficiently eradicated leukemia cells, but leukemia relapsed after CAR-T19 therapy. Our findings suggest that the absence of CD19 downmodulation in the STAb-T19 strategy, coupled with the continued antibody secretion, allows an efficient recruitment of the endogenous T-cell pool, resulting in fast and effective elimination of cancer cells that may prevent CD19-positive relapses frequently associated with CAR-T19 therapies.Keywords
All Related Versions
Funding Information
- European Research Council (CoG-2014-646903, PoC-2018-811220)
- Spanish Ministry of Science and Innovation (PID2019-105623RB-I00, SAF2016-75656-P, RTC-2017-5944-1, SAF-2019-108160-R, SAF2017-89437-P, PID2020-117323RB-100, PDC2021-121711-100)
- Carlos III Health Institute (PI20/01030, PI20/00822, PI16/00357, PI19/00132, PICI14/122, PI13/676, PIE13/33, PI18/775, DTS20/00089)
- CatSalut, Fundació La Caixa (CP042702)
- Spanish Association Against Cancer (AECC CICPF18030TORI, AECC 19084)
- CRIS Cancer Foundation (FCRIS-IFI-2018, FCRIS-IFI-2020)
- Spanish Ministry of Science and Innovation under a Ramon y Cajal grant (RYC2018-024442-I)
- Comunidad Autonoma de Madrid (PEJD-2018- PRE/BMD-8314)
- ISCIII (CM20/00004)
- Spanish Ministry of Science and Innovation (PRE2018-083445)
- Portuguese Foundation for Science and Technology (SFRH/BD/136574/2018)
This publication has 36 references indexed in Scilit:
- Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in miceBlood Cancer Journal, 2016
- T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive MalignanciesScientific Reports, 2016
- CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target CellsCancer Immunology Research, 2015
- Optimization of Heavy Chain and Light Chain Signal Peptides for High Level Expression of Therapeutic Antibodies in CHO CellsPLOS ONE, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applicationsOncoImmunology, 2014
- PotentIn vitroandIn vivoActivity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and LeukemiaCancer Research, 2008
- Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic ActivityCancer Research, 2008
- Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA × anti-CD3 diabodies from lentivirally transduced human lymphocytesCancer Gene Therapy, 2007
- Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cellsMolecular Immunology, 2006